Literature DB >> 18069728

Bayesian sample size for exploratory clinical trials incorporating historical data.

John Whitehead1, Elsa Valdés-Márquez, Patrick Johnson, Gordon Graham.   

Abstract

This paper presents a simple Bayesian approach to sample size determination in clinical trials. It is required that the trial should be large enough to ensure that the data collected will provide convincing evidence either that an experimental treatment is better than a control or that it fails to improve upon control by some clinically relevant difference. The method resembles standard frequentist formulations of the problem, and indeed in certain circumstances involving 'non-informative' prior information it leads to identical answers. In particular, unlike many Bayesian approaches to sample size determination, use is made of an alternative hypothesis that an experimental treatment is better than a control treatment by some specified magnitude. The approach is introduced in the context of testing whether a single stream of binary observations are consistent with a given success rate p(0). Next the case of comparing two independent streams of normally distributed responses is considered, first under the assumption that their common variance is known and then for unknown variance. Finally, the more general situation in which a large sample is to be collected and analysed according to the asymptotic properties of the score statistic is explored. (c) 2007 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2008        PMID: 18069728     DOI: 10.1002/sim.3140

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  Bayesian hierarchical modeling based on multisource exchangeability.

Authors:  Alexander M Kaizer; Joseph S Koopmeiners; Brian P Hobbs
Journal:  Biostatistics       Date:  2018-04-01       Impact factor: 5.899

2.  A two-stage Bayesian design with sample size reestimation and subgroup analysis for phase II binary response trials.

Authors:  Wei Zhong; Joseph S Koopmeiners; Bradley P Carlin
Journal:  Contemp Clin Trials       Date:  2013-04-11       Impact factor: 2.226

3.  Bayesian methods for the design and interpretation of clinical trials in very rare diseases.

Authors:  Lisa V Hampson; John Whitehead; Despina Eleftheriou; Paul Brogan
Journal:  Stat Med       Date:  2014-06-23       Impact factor: 2.373

4.  Trial design for evaluating novel treatments during an outbreak of an infectious disease.

Authors:  John Whitehead; Piero Olliaro; Trudie Lang; Peter Horby
Journal:  Clin Trials       Date:  2016-01-14       Impact factor: 2.486

5.  Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma.

Authors:  P Dutton; S B Love; L Billingham; A B Hassan
Journal:  Stat Methods Med Res       Date:  2016-09-01       Impact factor: 3.021

6.  Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study.

Authors:  Tomokazu Aoki; Naoki Kagawa; Kazuhiko Sugiyama; Toshihiko Wakabayashi; Yoshiki Arakawa; Shigeru Yamaguchi; Shota Tanaka; Eiichi Ishikawa; Yoshihiro Muragaki; Motoo Nagane; Mitsutoshi Nakada; Satoshi Suehiro; Nobuhiro Hata; Junichiro Kuroda; Yoshitaka Narita; Yukihiko Sonoda; Yasuo Iwadate; Manabu Natsumeda; Yoichi Nakazato; Hironobu Minami; Yuki Hirata; Shunsuke Hagihara; Ryo Nishikawa
Journal:  Int J Clin Oncol       Date:  2021-09-29       Impact factor: 3.402

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.